Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in four malaria endemic states of India.
Adolescent
Adult
Antimalarials
/ therapeutic use
Artemether, Lumefantrine Drug Combination
/ therapeutic use
Child
Child, Preschool
Endemic Diseases
/ prevention & control
Female
Humans
India
Infant
Malaria, Falciparum
/ prevention & control
Male
Middle Aged
Plasmodium falciparum
/ drug effects
Young Adult
Artemether-lumefantrine
Malaria
Plasmodium falciparum
Therapeutic efficacy
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
21 May 2021
21 May 2021
Historique:
received:
10
02
2021
accepted:
11
05
2021
entrez:
22
5
2021
pubmed:
23
5
2021
medline:
18
9
2021
Statut:
epublish
Résumé
Malaria is a major public health problem in India and accounts for about 88% of malaria burden in South-East Asia. India alone accounted for 2% of total malaria cases globally. Anti-malarial drug resistance is one of the major problems for malaria control and elimination programme. Artemether-lumefantrine (AL) is the first-line treatment of uncomplicated Plasmodium falciparum in north eastern states of India since 2013 after confirming the resistance against sulfadoxine-pyrimethamine. In the present study, therapeutic efficacy of artemether-lumefantrine and k13 polymorphism was assessed in uncomplicated P. falciparum malaria. This study was conducted at four community health centres located in Koraput district of Odisha, Bastar district of Chhattisgarh, Balaghat district of Madhya Pradesh and Gondia district of Maharashtra state. Patients with uncomplicated P. falciparum malaria were administered with fixed dose combination (6 doses) of artemether-lumefantrine for 3 days and clinical and parasitological response was recorded up to 28 days as per World Health Organization protocol. Nucleotide sequencing of msp1 and msp2 gene was performed to differentiate between recrudescence and reinfection. Amplification and sequencing of k13 propeller gene region covering codon 450-680 was also carried out to identify the polymorphism. A total 376 malaria patients who fulfilled the enrolment criteria as well as consented for the study were enrolled. Total 356 patients were followed up successfully up to 28 days. Overall, the adequate clinical and parasitological response was 98.9% and 99.4% with and without PCR correction respectively. No case of early treatment failure was observed. However, four cases (1.1%) of late parasitological failure were found from the Bastar district of Chhattisgarh. Genotyping of msp1 and msp2 confirmed 2 cases each of recrudescence and reinfection, respectively. Mutation analysis of k13 propeller gene showed one non-synonymous mutation Q613H in one isolate from Bastar. The study results showed that artemether-lumefantrine is highly effective in the treatment of uncomplicated P. falciparum malaria among all age groups. No functional mutation in k13 was found in the study area. The data from this study will be helpful in implementation of artemether-lumefantrine in case of treatment failure by artesunate plus sulfadoxine-pyrimethamine.
Sections du résumé
BACKGROUND
BACKGROUND
Malaria is a major public health problem in India and accounts for about 88% of malaria burden in South-East Asia. India alone accounted for 2% of total malaria cases globally. Anti-malarial drug resistance is one of the major problems for malaria control and elimination programme. Artemether-lumefantrine (AL) is the first-line treatment of uncomplicated Plasmodium falciparum in north eastern states of India since 2013 after confirming the resistance against sulfadoxine-pyrimethamine. In the present study, therapeutic efficacy of artemether-lumefantrine and k13 polymorphism was assessed in uncomplicated P. falciparum malaria.
METHODS
METHODS
This study was conducted at four community health centres located in Koraput district of Odisha, Bastar district of Chhattisgarh, Balaghat district of Madhya Pradesh and Gondia district of Maharashtra state. Patients with uncomplicated P. falciparum malaria were administered with fixed dose combination (6 doses) of artemether-lumefantrine for 3 days and clinical and parasitological response was recorded up to 28 days as per World Health Organization protocol. Nucleotide sequencing of msp1 and msp2 gene was performed to differentiate between recrudescence and reinfection. Amplification and sequencing of k13 propeller gene region covering codon 450-680 was also carried out to identify the polymorphism.
RESULTS
RESULTS
A total 376 malaria patients who fulfilled the enrolment criteria as well as consented for the study were enrolled. Total 356 patients were followed up successfully up to 28 days. Overall, the adequate clinical and parasitological response was 98.9% and 99.4% with and without PCR correction respectively. No case of early treatment failure was observed. However, four cases (1.1%) of late parasitological failure were found from the Bastar district of Chhattisgarh. Genotyping of msp1 and msp2 confirmed 2 cases each of recrudescence and reinfection, respectively. Mutation analysis of k13 propeller gene showed one non-synonymous mutation Q613H in one isolate from Bastar.
CONCLUSIONS
CONCLUSIONS
The study results showed that artemether-lumefantrine is highly effective in the treatment of uncomplicated P. falciparum malaria among all age groups. No functional mutation in k13 was found in the study area. The data from this study will be helpful in implementation of artemether-lumefantrine in case of treatment failure by artesunate plus sulfadoxine-pyrimethamine.
Identifiants
pubmed: 34020652
doi: 10.1186/s12936-021-03762-7
pii: 10.1186/s12936-021-03762-7
pmc: PMC8139028
doi:
Substances chimiques
Antimalarials
0
Artemether, Lumefantrine Drug Combination
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
229Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Références
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):69-78
pubmed: 18165477
Emerg Infect Dis. 2015 Oct;21(10):1853-7
pubmed: 26401635
Nature. 2014 Jan 2;505(7481):50-5
pubmed: 24352242
Lancet Infect Dis. 2011 Jan;11(1):57-64
pubmed: 21183147
Trop Med Int Health. 2013 May;18(5):578-87
pubmed: 23489465
Trop Med Int Health. 2010 Jan;15(1):33-40
pubmed: 19912592
Antimicrob Agents Chemother. 2015 Oct 26;60(1):624-7
pubmed: 26503652
Malar J. 2018 Oct 5;17(1):350
pubmed: 30290825
J Vector Borne Dis. 2004 Sep-Dec;41(3-4):45-53
pubmed: 15672556
Malar J. 2018 Jul 4;17(1):246
pubmed: 29973212
Sci Rep. 2017 Dec 4;7(1):16860
pubmed: 29203789
Malar J. 2016 Oct 13;15(1):498
pubmed: 27737665
Malar Res Treat. 2011;2011:703730
pubmed: 22312573
Antimicrob Agents Chemother. 2015 May;59(5):2548-53
pubmed: 25691626
Am J Trop Med Hyg. 2018 Jan;98(1):88-94
pubmed: 29141762
Lancet. 2020 Apr 25;395(10233):1345-1360
pubmed: 32171078
N Engl J Med. 2014 Jul 31;371(5):411-23
pubmed: 25075834
Malar J. 2009 May 19;8:107
pubmed: 19454000
Mol Biochem Parasitol. 1993 Apr;58(2):283-92
pubmed: 8479452